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10 Alzheimer’s disease (AD) is a progressive neurological
11 disorder, which represents the most common form of
12 dementia, one of the major causes of disability in
13 later life. Age is the greatest risk factor for AD, which
14 typically affects people aged 65 years and over, with
15 an age-standardised prevalence of 4.4 [1]. However,
16 AD is not a normal part of ageing and advanced age
17 alone does not justify the disease. Several pathways
18 have been implicated in AD pathophysiology, the most
19 described is the neurodegenerative one, which lead to
20 the brain accumulation of beta-amyloid and neurofibril-
21 lary tangles, aggregations of hyperphosphorylated tau
22 protein, macroscopically resulting in brain atrophy due
23 to neuronal death [2]. These pathological hallmarks of
24 AD have been recently incorporated in the new recommen-
25 dations on diagnostic guidelines for AD, which describe
26 different stages of the disease, including its preclinical and
27 symptomatic pre-dementia phases [3].
28 Genetics accounts for less than 3% of AD, familiar AD
29 at early onset, resulting from mutations in three genes, i.e.
30 APP, PS1 and PS2. Furthermore, the Apolipoprotein E4
31 (ApoE4) genotype is the only, robust, susceptibility gene
32 for AD [2], although meta-analysis and genome scanning
33 have revealed several susceptibility loci with low odds ra-
34 tios [4,5]. Overall, multiple gene-gene and environment
35 interactions cause AD; however, various risk factors differ-
36 ently act throughout ageing [2,6]. Large data have been
37 collected in the last two decades regarding the putative
38 role of vascular disease, including systemic atherosclerosis,
39 high blood pressure, diabetes, high level of cholesterol,
40 tobacco smoking, as well as other vascular risk factors,
41 as pathogenetic cause of AD [6-8]. However, a central
42 role for systemic inflammation has been claimed also
43 taking into account previously reported data, traumatic
44 brain injury and oxidative stress [9-13]. Indeed, only a
45small percentage of people aged 80 years or over has a
46pure neurodegenerative AD, and mixed dementia with
47vascular and/or inflammatory components are present
48[14]. Peripheral inflammation is indeed present in early
49stage of AD and is higher than that observed during
50non-pathological ageing [13]. Moreover, an altered in-
51flammatory regulation is also present in Mild Cognitive
52Impairment (MCI), the intermediate stage between the
53expected cognitive decline of normal ageing and the
54more serious decline of dementia [15], and correlates
55with the progression to AD [13].
56Accordingly, acute episodes of systemic inflammation
57with increased levels of inflammatory mediator tumor
58necrosis factor-alpha, which are associated with AD [5],
59have been shown to be associated with long-term cognitive
60decline in a prospective cohort study of subjects with AD
61[16]. The missing link between central neuro-inflammation
62and peripheral inflammatory state might be represented by
63infectious factors [17].
64The possibility of an infectious aetiology for AD has
65been repeatedly proposed over the past three decades,
66suggesting the role of viral and bacterial chronic infections
67as causative inflammatory pathway for AD. Concerning
68bacterial infections, data from a recent meta-analysis dem-
69onstrated that Spirochetal or Chlamydophila Pneumoniae
70infections were strongly associated with AD [18].
71More interestingly, the role of chronic inflammation in
72periodontal disease (PD) has been suggested over the
73last decade as a potential risk factor for AD [17,19-21].
74In particular, researchers from US found that antibody
75levels to specific oral pathogens were significantly in-
76creased at baseline serum draw in subjects who lately
77developed MCI or AD, thus suggesting that PD could
78potentially contribute to the risk of AD [21]. In cases
79of severe PD, pro-inflammatory molecules may induce
80a systemic inflammation and may, therefore, access the
81brain via systemic circulation. Pro-inflammatory molecules,
82derived locally from periodontal tissue, may stimulate tri-
83geminal nerve fibres, leading to an increase in the number
84of brain cytokines. These cytokines may act on the already
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85 primed glial cells, resulting in an amplified reaction and
86 possible progression of AD [18,20].
87 The concept of a viral role in AD, specifically of herpes
88 simplex virus type 1 (HSV-1), was first proposed several
89 decades ago. However, it was only in 1991 that by poly-
90 merase chain reaction it was looked for HSV-1 DNA in
91 autopsy brain specimens. In all specimens from 8 AD
92 patients and 6 normal individuals (from temporal, frontal
93 and hippocampal lobes), the authors found viral sequences
94 (22). It was postulated that factors such as number or
95 expression of viral genes and host susceptibility might be
96 related to incidence of AD [22,23].
97 HSV-1 is a ubiquitous virus that affects more than
98 80% of people over 65 worldwide. It is a neurotropic
99 double-stranded DNA virus that primarily infects epithe-
100 lial cells of oral and nasal mucosa, where virus undergoes
101 lytic replication; the newly produced viral particles may
102 enter sensory neurons and, by axonal transport, reach the
103 trigeminal ganglion where they usually establish a latent
104 infection. The trigeminal ganglion neurons also project to
105 the trigeminal nuclei located in the brainstem. From here,
106 neurons project to the thalamus to finally reach the sen-
107 sory cortex. This is the path through which the reactivated
108 virus may reach the central nervous system (CNS), where
109 it may cause acute neurological disorders like encephalitis
110 or a mild, clinically asymptomatic, infection, or establish
111 lifelong latent infection. It has been proposed that
112 virus is normally latent in many elderly brains but
113 reactivates periodically, as in the peripheral nervous
114 system, under certain conditions, for example stress,
115 immunosuppression, and peripheral infection, causing
116 cumulative damage and eventually development of AD
117 [17,23,24]. Thus, elderly immunosenescence might be
118 responsible for its reactivation [17]. Several epidemio-
119 logical studies have shown, using serological data, an
120 association between systemic infections and cognitive
121 decline, with HSV1 particularly implicated [17,24,25].
122 A very recent Swedish nested case–control study
123 showed that the presence of anti-HSV-1 IgG antibodies
124 doubled the risk for AD in persons for whom plasma
125 was collected more than 6.6 years before the AD diagnosis
126 [26]. Of interest, this risk increased in subject aged over
127 60 years and among females. Another study from Italy
128 reported that elevated serum HSV-1 antibody titres corre-
129 lated with cortical grey matter volume [27].
130 It is interesting to note that other herpes viruses share
131 the ability to become latent in the infected host and
132 eventually latently infect neurons. However, investiga-
133 tions focused on different viruses of the herpes family,
134 such as human cytomegalovirus (CMV), Epstein-Barr
135 virus (EBV) or human herpes virus 6 (HHV-6) in AD
136 are limited [17]. A recent work showed that increased
137 CMV antibody levels were present in the elderly who
138 developed clinical AD during a five years follow-up [28].
139In a study of deceased and autopsied subjects from a
140clinical-pathological community cohort, the authors
141found associations of CMV-related immunologic and
142virologic characteristics with AD neuropathology and
143additional trends toward associations with clinical diagno-
144sis [29]. Nonetheless, these findings could equally well be
145explained by an indirect effect since reactivation of HSV-1
146is associated with CMV and age, perhaps via CMV-
147induced immunosenescence [30,31]. On the other
148hand, a few data present in literature concerning the
149serological association between EBV or HHV-6 and
150AD could be explained by a similar indirect effect. Both
151HSV-1 reactivation and EBV and HHV-6 antibody stimu-
152lation can, in fact, be triggered by T immunosenescence
153that is stronger in AD than in control elderly [32]. As an
154alternative, but not mutually exclusive, possibility, EBV
155and HHV-6 titles might indicate a systemic inflammation
156responsible for HSV-1 reactivation [33].
157Indeed, and as reviewed by Itzhaki [23], there is evi-
158dence for direct possible pathophysiological mechanisms
159in AD only for HSV-1 since reactivated HSV-1 can cause
160direct and inflammatory damage in CNS. Implicating
161HSV-1 further in AD is the discovery that HSV-1 DNA
162is specifically localized in amyloid plaques in AD. In
163addition, data by several groups show that HSV-1 infection
164of cells in culture causes formation of β-amiloid, datum
165initially found by Wozniak et al., [34] and of AD-like
166tau, datum initially found by Zambrano et al. [35].
167Other relevant, harmful effects of infection include the
168following: dynamic interactions between HSV-1 and
169amyloid precursor protein (APP), which would affect
170both viral and APP transport [23].
171As previously stated, findings from a genome-wide
172association study in a large cohort of patients with AD
173showed that a limited set of genes were associated
174with the disease. Licastro and co-workers [17,36] and
175manuscript submitted suggest that the polymorphism
176association in some of these genes is consistent with a
177non-conventional interpretation of AD aetiology. These
178data suggest that differential genetic backgrounds in genes
179regulating immune defences against herpes viruses are as-
180sociated with age-related cognitive deterioration and AD.
181Cycles of virus latency/infections may therefore contribute
182to neurodegeneration associated with AD in genetically
183predisposed elderly, leading to neuronal loss, inflamma-
184tion and amyloid deposition.
185However, only a few prospective cohort studies have
186confirmed the role of viral and bacteria infections in
187AD. Overall, available data suggest a link between
188chronic infections and increased risk for AD, possibly
189through a low-grade, chronic infection and inflamma-
190tion in individuals who have inherent susceptibility
191traits. However, the majority of researches conducted
192have been cross-sectional, observational studies, which
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193 include relatively small hospital-based samples with in-
194 herent problems of selection and residual confounding.
195 Accordingly, further prospective, population-based studies
196 conducted in large cohorts investigating the link between
197 infection and AD are warranted, taking into account
198 APOE typing because of its involvement both in AD and
199 chronic infections [2,37,38]. In any case, successful treat-
200 ment of chronic infections is a challenging but mandatory
201 goal to improve the quality of life in the elderly.
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